Humanization of an anti-ICAM-1 antibody with over 50-fold affinity and functional improvement

Journal of Immunological Methods

Volumn 275, Issue 1-2, 2003, Pages 31-40

  Luo, Guang X ^a   Kohlstaedt, Lori A ^a   Charles, Catherine H ^a   Gorfain, Elliott ^a   Morantte, Ianessa ^a   Williams, Jimmy H ^a   Fang, Fang ^a  

^a Perlan Therapeutics Inc   (United States)

Author keywords

Anti ICAM 1 antibody; Antibody humanization; CDR grafting; Human rhinovirus

Indexed keywords

INTERCELLULAR ADHESION MOLECULE 1 ANTIBODY; MONOCLONAL ANTIBODY; SINGLE CHAIN FRAGMENT VARIABLE ANTIBODY;

ARTICLE; BINDING AFFINITY; CELL PROTECTION; COMPLEMENTARITY DETERMINING REGION; HUMAN RHINOVIRUS; MOLECULAR MODEL; PRIORITY JOURNAL; VIRUS INFECTION;

HUMAN RHINOVIRUS SP.; RHINOVIRUS;

EID: 0037376291     PISSN: 00221759     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0022-1759(02)00542-2     Document Type: Article

References (30)

1. Bella J., Kolatkar P.R., Marlor C.W., Greve J.M., Rossmann M.G. The structure of the two amino-terminal domains of human ICAM-1 suggests how it functions as a rhinovirus receptor and as an LFA-1 integrin ligand. Proc. Natl. Acad. Sci. U. S. A. 95:1998;4140-4145.
2. Carter P., Presta L., Gorman C.M., Ridgway J.B.B., Henner D., Wong W.L.T., Rowland A.M., Kotts C., Carver M.E., Shepard H.M. Humanization of an anti-p185 HER2 antibody for human cancer therapy. Proc. Natl. Acad. Sci. U. S. A. 89:1992;4285-4289.
3. Chothia C., Lesk A.M. Canonical structures for the hypervariable regions of immunoglobulins. J. Mol. Biol. 196:1987;901-917.
4. Chothia C., Lesk A.M., Tramontano A., Levitt M., Smith-Gill S.J., Air G., Sheriff S., Padlan E.A., Davies D., Tulip W.R., Colman P.M., Spinelli S., Alzari P.M., Poljak R.J. Conformations of immunoglobulin hypervariable regions. Nature. 342:1989;877-883.
5. Chothia C., Lesk A.M., Gherardi E., Tomlinson I.M., Walter G., Marks J.D., Llewelyn M.B., Winter G. Structural repertoire of the human VH segments. J. Mol. Biol. 227:1992;799-817.
6. Co M.S., Deschamps M., Whitley R.J., Queen C. Humanized antibodies for antiviral therapy. Proc. Natl. Acad. Sci. U. S. A. 88:1991;2869-2873.
7. Co M.S., Avdalovic N.M., Caron P.C., Avdalovic M.V., Scheinberg D.A., Queen C. Chimeric and humanized antibodies with specificity for the CD33 antigen. J. Immunol. 148:1992;1149-1154.
8. Colonno R.J. Virus receptors: the Achilles' heel of human rhinoviruses. Block T.et al. Innovation in Antiviral Development and the Detection of Virus Infection. 1992;61-70 Plenum Press, New York.
9. Colonno, R.J., Condra, J.H., Tomassini, J.E., Sardana, V.V., 1991. European Patent Application #91201243.2. Publication number: 0 459 577 A2.
10. Dustin M.L., Rothlein R., Bhan A.K., Dinarello C.A., Springer T.A. Induction by IL 1 and interferon-gamma: tissue distribution, biochemistry, and function of a natural adherence molecule (ICAM-1). J. Immunol. 137:1986;245-254.
11. Foote J., Winter G. Antibody framework residues affecting the conformation of the hypervariable loops. J. Mol. Biol. 224:1992;487-499.
12. Greve J.M., Davis G., Meyer A.M., Forte C.P., Yost S.C., Marlor C.W., Kamarck M.E., McClelland A. The major human rhinovirus receptor is ICAM-1. Cell. 56:1989;839-847.
13. Guex N., Peitsch M.C. SWISS-MODEL and the Swiss-PdbViewer: an environment for comparative protein modeling. Electrophoresis. 18:1997;2714-2723.
14. Hayden F.G., Gwaltney J.M., Colonno R.J. Modification of experimental rhinovirus colds by receptor blockade. Antivir. Res. 9:1988;233-247.
15. Huguenel E.D., Cohn D., Dockum D.P., Greve J.M., Fournel M.A., Hammond L., Irwin R., Mahoney J., McClelland A., Muchmore E., Ohlin A.C., Scuderi P. Prevention of rhinovirus infection in chimpanzees by soluble intercellular adhesion molecule-1. Am. J. Respir. Crit. Care Med. 155(4):1997;1206-1210.
16. Jones P.T., Dear P.H., Foote J., Neuberger M.S., Winter G. Replacing the complementarity-determining regions in a human antibody with those from a mouse. Nature. 321:1986;522-525.
17. Kabat E.A., Wu T.T., Reid-Miller I.J. Paul W.E. Fundamental Immunology. 1984;595-644 Raven Press, New York.
18. Lineberger D.W., Graham D.J., Tomassini J.E., Colonno R.J. Antibodies that block rhinovirus attachment map to domain 1 of the major group receptor. J. Virol. 64:1990;2582-2587.
19. Malby R.L., McCoy A.J., Kortt A.A., Hudson P.J., Colman P.M. Three-dimensional structures of single-chain Fv-neuraminidase complexes. J. Mol. Biol. 279:1998;901-910.
20. Padlan E.A. A possible procedure for reducing the immunogenicity of antibody variable domains while preserving their ligand-binding properties. Mol. Immunol. 28:1991;489-498.
21. Padlan E.A. Anatomy of the antibody molecule. Mol. Immunol. 31:1994;169-217.
22. Presta L.G., Lahr S.J., Shields R.L., Porter J.P., Gorman C.M., Fendly B.M., Jardieu P.M. Humanization of an antibody directed against IgE. J. Immunol. 151:1993;2623-2632.
23. Queen C., Schneider W.P., Selick H.E., Payne P.W., Landolfi N.F., Duncan J.F., Avdalovic N.M., Levitt M., Junghans R.P., Waldmann T.A. A humanized antibody that binds to the interleukin 2 receptor. Proc. Natl. Acad. Sci. U. S. A. 86:1989;10029-10033.
24. Riechmann L., Clark M., Waldmann H., Winter G. Reshaping human antibodies for therapy. Nature. 332:1988;323-327.
25. Smith C.W., Marlin S.D., Rothlein R., Toman C., Anderson D.C. Cooperative interactions of LFA-1 and Mac-1 with intercellular adhesion molecule-1 in facilitating adherence and transendothelial migration of human neutrophils in vitro. J. Clin. Invest. 83:1989;2008-2017.
26. Staunton D.E., Merluzzi V.J., Rothlein R., Barton R., Marlin S.D., Springer T.A. A cell adhesion molecule, ICAM-1, is the major surface receptor for rhinoviruses. Cell. 56:1989;849-853.
27. Tomassini J.E., Graham D., DeWitt C.M., Lineberger D.W., Rodkey J.A., Colonno R.J. cDNA cloning reveals that the major group rhinovirus receptor on HeLa cells is intercellular adhesion molecule 1. Proc. Natl. Acad. Sci. U. S. A. 86:1989;4907-4911.
28. Tormo J., Blaas D., Parry N.R., Rowlands D., Stuart D., Fita I. Crystal structure of a human rhinovirus neutralizing antibody complexed with a peptide derived from viral capsid protein VP2. EMBO J. 13:1994;2247-2256.
29. Turner R.B., Wecker M.T., Pohl G., Witek T.J., McNally E., George R.S., Winther B., Hayden F.G. Efficacy of tremacamra, a soluble intercellular adhesion molecule 1, for experimental rhinovirus infection: a randomized clinical trial. JAMA. 281:1999;1797-1804.
30. Verhoeyen M., Milstein C., Winter G. Reshaping human antibodies: grafting an antilysozyme activity. Science. 239:1988;1534-1536.